JP4658613B2 - 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法 - Google Patents

臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法 Download PDF

Info

Publication number
JP4658613B2
JP4658613B2 JP2004561083A JP2004561083A JP4658613B2 JP 4658613 B2 JP4658613 B2 JP 4658613B2 JP 2004561083 A JP2004561083 A JP 2004561083A JP 2004561083 A JP2004561083 A JP 2004561083A JP 4658613 B2 JP4658613 B2 JP 4658613B2
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical formulation
escitalopram
treatment
hydrobromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004561083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514952A5 (enExample
JP2006514952A (ja
Inventor
マーテル・ローレンス
ダンサー・ロベルト
ぺーターセン・ハンス
エレゴード・ペーター
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4658613(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2006514952A publication Critical patent/JP2006514952A/ja
Publication of JP2006514952A5 publication Critical patent/JP2006514952A5/ja
Application granted granted Critical
Publication of JP4658613B2 publication Critical patent/JP4658613B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2004561083A 2002-12-23 2003-12-18 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法 Expired - Lifetime JP4658613B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
PCT/DK2003/000902 WO2004056791A1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010235287A Division JP2011037893A (ja) 2002-12-23 2010-10-20 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法

Publications (3)

Publication Number Publication Date
JP2006514952A JP2006514952A (ja) 2006-05-18
JP2006514952A5 JP2006514952A5 (enExample) 2007-01-18
JP4658613B2 true JP4658613B2 (ja) 2011-03-23

Family

ID=32668635

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004561083A Expired - Lifetime JP4658613B2 (ja) 2002-12-23 2003-12-18 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法
JP2010235287A Withdrawn JP2011037893A (ja) 2002-12-23 2010-10-20 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010235287A Withdrawn JP2011037893A (ja) 2002-12-23 2010-10-20 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法

Country Status (32)

Country Link
US (1) US20040167209A1 (enExample)
EP (1) EP1578738B1 (enExample)
JP (2) JP4658613B2 (enExample)
KR (1) KR20050086933A (enExample)
CN (1) CN100349885C (enExample)
AR (1) AR042652A1 (enExample)
AT (1) ATE388947T1 (enExample)
AU (1) AU2003287919B2 (enExample)
BR (1) BR0317623A (enExample)
CA (1) CA2511142A1 (enExample)
CY (1) CY1107451T1 (enExample)
DE (1) DE60319739T2 (enExample)
DK (1) DK1578738T3 (enExample)
EA (1) EA013116B1 (enExample)
EG (1) EG24729A (enExample)
ES (1) ES2298595T3 (enExample)
IL (1) IL169125A0 (enExample)
IS (1) IS2654B (enExample)
ME (1) MEP5808A (enExample)
MX (1) MXPA05005772A (enExample)
MY (1) MY135468A (enExample)
NO (1) NO20053595L (enExample)
NZ (1) NZ540281A (enExample)
PE (1) PE20040924A1 (enExample)
PL (1) PL378275A1 (enExample)
PT (1) PT1578738E (enExample)
RS (1) RS51092B (enExample)
TW (1) TW200501943A (enExample)
UA (1) UA80170C2 (enExample)
UY (1) UY28148A1 (enExample)
WO (1) WO2004056791A1 (enExample)
ZA (1) ZA200504109B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037893A (ja) * 2002-12-23 2011-02-24 H Lundbeck As 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
JP5501615B2 (ja) * 2006-07-11 2014-05-28 田辺三菱製薬株式会社 モルホリン化合物の塩
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ATE230738T1 (de) * 1998-10-20 2003-01-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
PT1298124E (pt) * 1999-10-25 2007-05-31 Lundbeck & Co As H Método para a preparação de citalopram
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
WO2002046340A1 (de) * 2000-12-04 2002-06-13 Dr. Frische Gmbh Verfahren zur herstellung von fettsaüreestern
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037893A (ja) * 2002-12-23 2011-02-24 H Lundbeck As 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法

Also Published As

Publication number Publication date
AR042652A1 (es) 2005-06-29
ATE388947T1 (de) 2008-03-15
DE60319739T2 (de) 2008-07-17
EA013116B1 (ru) 2010-02-26
WO2004056791A1 (en) 2004-07-08
RS20050487A (sr) 2007-06-04
IS2654B (is) 2010-08-15
AU2003287919A1 (en) 2004-07-14
ZA200504109B (en) 2006-08-30
JP2011037893A (ja) 2011-02-24
KR20050086933A (ko) 2005-08-30
CA2511142A1 (en) 2004-07-08
EP1578738B1 (en) 2008-03-12
PT1578738E (pt) 2008-04-11
DK1578738T3 (da) 2008-06-30
PE20040924A1 (es) 2004-12-11
MY135468A (en) 2008-04-30
AU2003287919B2 (en) 2009-11-12
PL378275A1 (pl) 2006-03-20
EA200501046A1 (ru) 2005-12-29
DE60319739D1 (de) 2008-04-24
CN1726202A (zh) 2006-01-25
ES2298595T3 (es) 2008-05-16
CY1107451T1 (el) 2012-12-19
CN100349885C (zh) 2007-11-21
MXPA05005772A (es) 2005-08-16
TW200501943A (en) 2005-01-16
RS51092B (sr) 2010-10-31
NZ540281A (en) 2008-07-31
MEP5808A (xx) 2010-02-10
JP2006514952A (ja) 2006-05-18
EG24729A (en) 2010-06-21
UY28148A1 (es) 2004-09-30
EP1578738A1 (en) 2005-09-28
IS7848A (is) 2005-05-17
BR0317623A (pt) 2005-11-29
US20040167209A1 (en) 2004-08-26
HK1087708A1 (en) 2006-10-20
NO20053595L (no) 2005-09-05
UA80170C2 (en) 2007-08-27
IL169125A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
JP2011037893A (ja) 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法
EP1173431B2 (en) Method for the preparation of citalopram
US6509483B2 (en) Method for the preparation of citalopram
BR9917368B1 (pt) mÉtodo para preparaÇço de citalopram.
US20030114692A1 (en) Method for the preparation of citalopram
AU2001279609A1 (en) Method for the preparation of citalopram
JP4505335B2 (ja) ラセミ体シタロプラムジオール（ｒａｃｅｍｉｃｃｉｔａｌｏｐｒａｍｄｉｏｌ）および／またはＳ−もしくはＲ−シタロプラムジオールの製造方法、およびラセミ体シタロプラム、Ｒ−シタロプラムおよび／またはＳ−シタロプラムを製造するために、上記ジオールを使用する方法。
AU2001240469A1 (en) Method for the preparation of citalopram
US8288568B2 (en) Process for the preparation of escitalopram
HK1087708B (en) Escitalopram hydrobromide and a method for the preparation thereof
EP1485367B1 (en) Purified citalopram salts
EP2017271A1 (en) Process for the preparation of escitalopram
FI118765B (fi) Menetelmä sitalopraamin valmistamiseksi
WO2003042202A1 (en) Isobenzofuran derivatives

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100706

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101214

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101224

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4658613

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term